Medical Devices Provider Boston Scientific Cardiovascular Segment Sees Traction In Q3, Company Adjusts Annual Outlook
Portfolio Pulse from Anusuya Lahiri
Boston Scientific Corp (NYSE:BSX) reported Q3 revenues of $3.53 billion, surpassing Wall Street's estimate of $3.48 billion. The company's sales increased by 11.2% on a reported basis, 11.1% operationally, and 10.2% organically, beating management's estimate of 8.5% - 10.5%. The adjusted EPS was $0.50, higher than the consensus of $0.48. The company revised its FY23 revenue growth guidance to 11% and forecasts an adjusted EPS of $1.99 - $2.02.
October 26, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific Corp reported better than expected Q3 results and revised its FY23 revenue growth guidance upwards. This could positively impact the company's stock.
Boston Scientific Corp reported Q3 revenues and adjusted EPS that beat Wall Street's estimates. Additionally, the company revised its FY23 revenue growth guidance upwards. This positive financial performance and optimistic outlook could lead to an increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100